Highest-materiality recent filing
Protagonist Q2 net income $162.8M; ICOTYDE launch, rusfertide PDUFA in Aug 2026
Q2 2026 net income $162.8M ($2.47 basic EPS) vs net loss $34.8M in Q2 2025; revenue $213.5M from Takeda opt-out and J&J milestones.
Protagonist Therapeutics stockholders approve 2026 equity plan, adding 650K new shares
Stockholders approved adoption of 2026 Equity Incentive Plan, replacing 2016 plan; adds 650,000 new shares plus carryover from prior plan and returning shares.
Net income $3.8M ($0.05 diluted EPS) vs net loss $11.7M in Q1 2025; revenue $56.4M incl. $50M ICOTYDE milestone from J&J.
Protagonist Q4 net loss $44.4M ($0.69/share); rusfertide opt-out expected Q2 2026
Q4 2025 net loss $44.4M ($0.69 per share) vs Q4 2024 net income $131.7M ($2.11 per share); FY2025 loss $130.1M ($2.05) vs FY2024 income $275.2M ($4.47).
Icotrokinra (oral IL-23R) NDA for psoriasis filed Jul '25; Phase 3 ICONIC-UC and ICONIC-CD initiated Q4 '25; superiority vs deucravacitinib achieved.
Protagonist Q3 net loss $39.3M (-$0.62); cash $678.8M; icotrokinra filed, rusfertide NDA expected Q4
Net loss of $39.3M ($0.62 diluted EPS loss) vs $33.2M loss in Q3 2024.
Protagonist Q2 net loss $34.8M; icotrokinra NDA filed, rusfertide NDA on track
Net loss $34.8M ($0.55/share) vs $30.6M in Q2 2024; license revenue $5.5M from Takeda.
Protagonist Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor
Harold Selick and Bryan Giraudo elected Class III directors with ~83% and ~79% of votes cast, respectively.
Protagonist Q1 EPS -$0.19; rusfertide Phase 3 positive, ASCO plenary June 1
Cash $697.9M (up from $559.2M Dec 2024); net loss $11.7M (-$0.19/sh) vs income $207.3M in Q1 2024.
Protagonist transitions rusfertide NDA regulatory leadership to Takeda
Takeda to lead regulatory strategy and NDA preparation for rusfertide in polycythemia vera; transition underway.
Icotrokinra shows positive Phase 2b UC (corrected p-value) and Phase 3 PsO top-line data
Phase 2b ANTHEM-UC: highest dose achieved 63.5% clinical response and 30.2% clinical remission at Wk12 vs 27.0% and 11.1% placebo; p-values corrected to <0.001 and <0.01.
Icotrokinra Phase 3 PsO hits 46% complete skin clearance; UC Phase 2b meets endpoint
Phase 3 ICONIC-LEAD: 46% of icotrokinra patients achieved IGA 0 (completely clear skin) at Week 24; 74% IGA 0/1.
77% of rusfertide patients achieved clinical response vs 33% placebo (p<0.0001) during weeks 20-32.
Protagonist reports Q4 net income $131.7M; cash $559.2M; upcoming Phase 3 readouts in March 2025
Net income of $131.7M in Q4 2024 ($2.11 basic EPS) vs $27.3M in Q4 2023; FY 2024 net income $275.2M vs net loss of $79.0M in FY 2023.
Protagonist Therapeutics appoints Suneel Gupta as EVP, Clinical Development
Effective Jan 1, 2025, Suneel Gupta transitioned from Chief Development Officer to EVP, Clinical Development.
Protagonist announces positive Phase 3 results for icotrokinra; earns $165M milestone
ICONIC-LEAD met co-primary endpoints: 64.7% achieved IGA 0/1, 49.6% PASI 90 at week 16 vs placebo 8.3% and 4.4%.
Protagonist Q3 net loss of $33.2M, cash $583M; key readouts expected in Q4 2024 and Q1 2025
Net loss of $33.2M ($0.54 per share) vs $34.1M loss in prior-year Q3.
Director Daniel N. Swisher Jr. resigns from Protagonist board; board reduced to six
Daniel N. Swisher Jr. resigned from the Board effective September 17, 2024; no disagreement with company operations.
Protagonist Q2 net loss $30.6M; cash $595.4M; JNJ-2113 Phase 3 data expected Q4 2024
Q2 net loss of $30.6M ($0.50/share) vs $38.5M loss in Q2 2023; six-month net income $176.7M from Takeda upfront.
Protagonist Therapeutics shareholders approve doubling of authorized common shares to 180M
Shareholders approved amendment to increase authorized common shares from 90M to 180M, effective June 21, 2024.
Protagonist Q1 net income $207.3M on $255M Takeda revenue; cash runway through Q4 2027
Net income of $207.3M ($3.26 diluted EPS) vs net loss of $33.7M in Q1 2023; revenue $255M from Takeda rusfertide license.
Protagonist reports Q4 profit, $300M Takeda deal extends cash runway through 2027
Entered worldwide Takeda collaboration for rusfertide; $300M upfront, US profit share, opt-out up to $400M.
Protagonist Therapeutics signs $300M upfront collaboration with Takeda for rusfertide
Takeda pays $300M upfront within 30 days of HSR clearance; 50/50 profit-loss share in U.S.
Protagonist details rusfertide Ph3 enrollment, JNJ-2113 milestones, cash runway through Q1 2026
Rusfertide VERIFY Ph3 enrollment expected to complete 1Q24; NDA filing planned for Q4 2024.
Rusfertide Phase 3 VERIFY study enrollment completion expected Q1 2024; primary endpoint similar to Phase 2.
Protagonist Q3 net loss $34.1M; earns $50M milestone from Janssen for JNJ-2113 Phase 3
Net loss of $34.1M ($0.58 per share) vs $31.2M loss in Q3 2022; R&D expenses rose to $30.7M.
Protagonist Therapeutics expands board to 7, appoints Daniel Swisher as director
Board increased from 6 to 7 directors; Daniel N. Swisher, Jr. appointed as Class I director effective Oct 26, 2023.
Protagonist Q2 net loss $38.5M; JNJ-2113 advances to Phase 3 in psoriasis
Net loss of $38.5M ($0.68/share) in Q2 2023 vs $41M loss in Q2 2022; cash $313.4M at June 30.
Phase 2b FRONTIER 1 trial of JNJ-2113 in moderate-to-severe psoriasis completed; Phase 3 psoriasis study initiation planned.
Protagonist Therapeutics receives Nasdaq non-compliance notice for audit committee vacancy
On June 27, 2023, Nasdaq confirmed Protagonist is not compliant with Listing Rule 5605 requiring an audit committee of at least three independent directors.
Annual meeting results: Patel elected, compensation and auditor approved
Elected Dinesh V. Patel as Class I director with 32,660,198 for, 8,874,076 withheld, 3,298,693 broker non-votes.
Protagonist Q1 net loss $33.7M; positive Phase 2b data for JNJ-2113; cash runway to 2025
Net loss $33.7M ($0.67/share) vs $20.9M loss in Q1 2022; license revenue zero (prior year $25.7M milestone).
Protagonist Therapeutics announces $100M public offering of 5M shares at $20/share
5,000,000 shares offered at $20.00 each; underwriters have 30-day option for 750,000 additional shares.
Net loss per share Q4 2022: $0.69 ($34.2M) vs $0.77 ($36.9M) in Q4 2021; full year 2022 net loss $127.4M.
Protagonist Therapeutics discloses limited SVB exposure, $13M at risk out of $231M total
Cash at SVB approximately $13M as of March 9, 2023; company considers exposure limited.
David Liu stepped down as Chief R&D Strategy Officer effective Jan 1, 2023, due to health reasons.
Protagonist Q3 net loss $31.2M, cash $267.4M; rusfertide Phase 3 enrollment delayed to H2 2023
Net loss $31.2M ($0.64 per share) vs $33.8M ($0.70) in Q3 2021; no license revenue vs $10.3M.
Protagonist Q2 net loss $41M; rusfertide Phase 3 enrollment slower, cash runway to end 2024
Net loss of $41.0M ($0.84 per share) vs $30.8M loss in Q2 2021; license revenue $0.9M.
Harold Selick and Bryan Giraudo elected Class III directors with 27.9M and 28.1M votes for, respectively.
Protagonist reports Q1 net loss $20.9M; initiates rusfertide Phase 3 VERIFY in PV
Q1 2022 net loss $20.9M ($0.43 per share) vs $24.0M ($0.54) in Q1 2021.
PN-943 Phase 2 IDEAL study shows 27.5% clinical remission at 150mg BID; 13% delta vs placebo
PN-943 150mg BID achieved 27.5% clinical remission vs 14.5% placebo (delta 13%, p=0.08); bio-naïve delta 16% (p=0.04).
FDA notified Protagonist of intent to rescind Breakthrough Therapy Designation for rusfertide in polycythemia vera; company requesting meeting to appeal.
Protagonist Therapeutics appoints Asif Ali as EVP, CFO effective April 18, 2022
Asif Ali, 48, appointed EVP, CFO; previously VP Finance & CAO at Theravance Biopharma (2018-2022) and VP Corp Controller at Depomed.
Protagonist Therapeutics CFO Don Kalkofen resigns effective April 1, 2022
CFO Don Kalkofen submitted resignation effective April 1, 2022.
Protagonist reports Q4 2021 net loss $36.9M; cash $326.9M; rusfertide Phase 3 to start Q1 2022
Net loss Q4 2021 $36.9M ($0.77/share) vs $18.9M ($0.48/share) in Q4 2020; full year loss $125.6M ($2.71/share) vs $66.2M ($1.92/share).
Protagonist Therapeutics increases inducement plan share reserve by 500,000 shares
Compensation Committee approved amendment to 2018 Inducement Plan on Feb 15, 2022, adding 500,000 shares (total 1,750,000).
Protagonist Q3 net loss $33.8M; rusfertide hold lifted, PN-235 advancing to Phase 2
Net loss $33.8M ($0.70/share) vs $7.8M loss in Q3 2020; revenue $10.3M (incl. $8M catch-up from Janssen amendment).
FDA places clinical hold on Protagonist's rusfertide program after tumor finding in mouse study
FDA clinical hold on all rusfertide studies after rasH2 mouse model showed benign/malignant subcutaneous skin tumors.
Royalty rate on rusfertide net sales reduced by 50% under settlement agreement.
Protagonist Q2 net loss $30.8M; rusfertide gets FDA Breakthrough Therapy; Phase 3 on track
Net loss $30.8M ($0.69/share) vs $19.4M ($0.59) in Q2 2020; cash $380.4M expected to fund through 2024.
Effective January 1, 2025, Suneel Gupta, Ph.D., Protagonist Therapeutics, Inc.’s Chief Development Officer, transitioned to Executive Vice President, Clinical Development.
On September 17, 2024, Daniel N. Swisher Jr., a member of the Board of Directors (the “Board”) of Protagonist Therapeutics, Inc. (the “Company”) and a member of the Audit Committee of the Board, resigned from the Board, effective September 17, 2024.
appointed Daniel N. Swisher, Jr. to serve as a Class I director
Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.’s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons.
On March 25, 2022, the Board of Directors of Protagonist Therapeutics, Inc. (the “Company”) approved the appointment of Asif Ali, 48, to the position of Executive Vice President, Chief Financial Officer, effective on commencement of Mr. Ali’s employment with the Company (April 18, 2022).
On March 17, 2022, Don Kalkofen, the Chief Financial Officer of Protagonist Therapeutics, Inc. (the “Company”), submitted his notice of resignation from his position as Chief Financial Officer of the Company to be effective on April 1, 2022.
Max materiality 1.00 · Median 0.70 · Most common event earnings